Navigation Links
Novocell Appoints Orville G. Kolterman, M.D. to Board of Directors

SAN DIEGO, Oct. 25 /PRNewswire/ -- Novocell, Inc., a leading stem cell engineering company, today announced the appointment of Orville G. Kolterman, M.D., Senior Vice President, Clinical & Regulatory Affairs of Amylin Pharmaceuticals, to the company's Board of Directors.

Dr. Kolterman joined Amylin in 1992 and has served as Senior Vice President, Clinical Affairs since February 1997 until present and as Senior Vice President, Regulatory Affairs since August 2005. At Amylin, Dr. Kolterman has been instrumental in the development of the company's first-in-class diabetes medicines, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection.

"Dr. Kolterman's breadth of experience, including the clinical development of successful diabetes therapeutics, will be invaluable to Novocell as we advance the development of our diabetes cell therapy and additional cell therapies," said Alan J. Lewis, President, Chief Executive Officer and Director of Novocell.

"I am pleased to join the Novocell board and look forward to working with the Company to help advance it's innovative platform technologies, including its human embryonic stem cell engineering, cell encapsulation and drug discovery efforts, which hold promise for the treatment of a range of chronic diseases," said Dr. Kolterman.

Prior to Amylin, Dr. Kolterman was Program Director of the General Clinical Research Center and Medical Director of the Diabetes Center at the University of California, San Diego (UCSD) Medical Center. He has also served as Assistant Professor of Medicine in the Endocrinology and Metabolism Division at the University of Colorado School of Medicine, Denver and was a member of the Diabetes Control and Complications Trial Study Group. Dr. Kolterman currently serves as a member of the Epidemiology of Diabetes Intervention and Complications Study. He is also a past-president of the California Affiliate of the American Diabetes Association. Dr. Kolterman received his M.D. from Stanford University School of Medicine.

About Novocell

Novocell is a stem cell engineering company with research operations in San Diego, CA, and Athens, GA, dedicated to creating, delivering, and commercializing cell and drug therapies to treat diseases including diabetes. Novocell is the first company to efficiently engineer human embryonic stem cells into definitive endoderm, the gatekeeper cells that differentiate into many other cells, tissues and organs. Novocell is focused on the development of a variety of technology platforms including stem cell engineering, cell encapsulation, and drug discovery. The company was founded in 1999 and merged with CyThera, Inc. and BresaGen, Inc. in 2004. For more information, visit

Media Contact:

Julie Rathbun

Rathbun Communications, Inc.

(206) 769-9219

SOURCE Novocell, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
(Date:11/25/2015)... November 25, 2015 The ... is a professional and in-depth study on the ...      (Logo: ) , ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ...
(Date:11/24/2015)... ... 24, 2015 , ... The United States Golf Association (USGA) today announced Dr. ... Award. Presented annually since 1961, the USGA Green Section Award recognizes an individual’s distinguished ... , Clarke, of Iselin, N.J., is an extension specialist of turfgrass pathology in ...
(Date:11/24/2015)... Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended September 30, ... Canadian dollars and presented under International Financial Reporting ... ," said Andrew Rae , President ... iCo-008 are not only value enriching for this ...
Breaking Biology Technology:
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/4/2015)... , November 4, 2015 ... new market report published by Transparency Market Research "Home Security ... Trends and Forecast 2015 - 2022", the global home security ... 30.3 bn by 2022. The market is estimated to ... period from 2015 to 2022. Rising security needs among ...
(Date:10/29/2015)... -- Daon, a global leader in mobile biometric authentication ... version of its IdentityX Platform , IdentityX v4.0. ... have already installed IdentityX v4.0 and are seeing ... UAF certified server component as an option and ... These customers include some of the largest and most ...
Breaking Biology News(10 mins):